MA71640A - Protéines de liaison au récepteur cannabinoïde de type 1 et leurs utilisations - Google Patents

Protéines de liaison au récepteur cannabinoïde de type 1 et leurs utilisations

Info

Publication number
MA71640A
MA71640A MA71640A MA71640A MA71640A MA 71640 A MA71640 A MA 71640A MA 71640 A MA71640 A MA 71640A MA 71640 A MA71640 A MA 71640A MA 71640 A MA71640 A MA 71640A
Authority
MA
Morocco
Prior art keywords
binding proteins
receptor type
cannabinoid receptor
cannabinoid
type
Prior art date
Application number
MA71640A
Other languages
English (en)
Inventor
Shu-Chen Lu
Irwin Chen
Su CHONG
Elizabeth Ann KILLION
Seog Joon Han
Kirill OXENOID
Weihsu Claire Chen
Venkata Nihal Pasumarthi
John BERGEN
Wadim L. MATOCHKO
Dawn WEISHUHN
Serina LI
Murielle Marie VENIANT-ELLISON
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of MA71640A publication Critical patent/MA71640A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA71640A 2022-07-28 2023-07-26 Protéines de liaison au récepteur cannabinoïde de type 1 et leurs utilisations MA71640A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263392891P 2022-07-28 2022-07-28
EP23847527.1A EP4562052A2 (fr) 2022-07-28 2023-07-26 Protéines de liaison au récepteur cannabinoïde de type 1 et leurs utilisations
PCT/US2023/071024 WO2024026351A2 (fr) 2022-07-28 2023-07-26 Protéines de liaison au récepteur cannabinoïde de type 1 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA71640A true MA71640A (fr) 2025-05-30

Family

ID=89707589

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71640A MA71640A (fr) 2022-07-28 2023-07-26 Protéines de liaison au récepteur cannabinoïde de type 1 et leurs utilisations

Country Status (19)

Country Link
US (1) US20250277029A1 (fr)
EP (1) EP4562052A2 (fr)
JP (1) JP2025524927A (fr)
KR (1) KR20250043535A (fr)
CN (1) CN119604534A (fr)
AR (1) AR130044A1 (fr)
AU (1) AU2023314633A1 (fr)
CA (1) CA3261907A1 (fr)
CL (1) CL2025000225A1 (fr)
CO (1) CO2025001993A2 (fr)
CR (1) CR20250064A (fr)
IL (1) IL318118A (fr)
JO (1) JOP20250016A1 (fr)
MA (1) MA71640A (fr)
MX (1) MX2025000954A (fr)
PE (1) PE20250735A1 (fr)
TW (1) TW202409089A (fr)
UY (1) UY40377A (fr)
WO (1) WO2024026351A2 (fr)

Also Published As

Publication number Publication date
WO2024026351A2 (fr) 2024-02-01
UY40377A (es) 2024-01-31
CA3261907A1 (fr) 2024-02-01
JOP20250016A1 (ar) 2025-01-23
TW202409089A (zh) 2024-03-01
CO2025001993A2 (es) 2025-03-06
CL2025000225A1 (es) 2025-06-13
US20250277029A1 (en) 2025-09-04
AR130044A1 (es) 2024-10-30
KR20250043535A (ko) 2025-03-28
AU2023314633A1 (en) 2025-01-16
IL318118A (en) 2025-02-01
JP2025524927A (ja) 2025-08-01
CR20250064A (es) 2025-06-26
EP4562052A2 (fr) 2025-06-04
CN119604534A (zh) 2025-03-11
MX2025000954A (es) 2025-03-07
PE20250735A1 (es) 2025-03-10

Similar Documents

Publication Publication Date Title
EP4200336A4 (fr) Anticorps anti-ror1 et protéines de liaison bispécifiques associées
EP4240490A4 (fr) Protéines de liaison reconnaissant l'antigène ha-1 et leurs utilisations
EP3997230A4 (fr) Molécules de liaison à la claudine-6 et leurs utilisations
EP4132969A4 (fr) Molécules de liaison à l'antigène anti-mésothéline et leurs utilisations
EP3902838A4 (fr) Fractions de liaison à cd30, récepteurs d'antigènes chimériques et leurs utilisations
EP3891181A4 (fr) Molécules de liaison à cd3 et leurs utilisations
EP3612218A4 (fr) Protéines de liaison à un antigène anti-trem2 et leurs utilisations
EP4065164A4 (fr) Anticorps anti-cd3 et anti-bcma, et protéines de liaison bispécifiques fabriquées à partir de ceux-ci
MA56029A (fr) Molécules de liaison au tigit et pd-1/tigit
EP3710484A4 (fr) Anticorps de liaison à ctla-4 et leurs utilisations
ATE388964T1 (de) Modifizierter löslicher t-zellen-rezeptor
EP4329803A4 (fr) Protéines de liaison pd-1 et tigit bispécifiques et leurs utilisations
EP3426680A4 (fr) Protéines de liaison au récepteur de l'activine de type 2 et leurs utilisations
EP3797164A4 (fr) Récepteurs d'antigènes chimériques avec domaines de liaison modifiés et utilisations associées
MA71622A (fr) Domaines de liaison à l'antigène cd98hc et leurs utilisations
MA56397A (fr) Protéines de liaison à l'il1rap
EP4323379A4 (fr) Peptides immunogènes magec2, protéines de liaison reconnaissant les peptides immunogènes magec2 et leurs utilisations
EP4262750A4 (fr) Formulations de protéines et leurs utilisations
EP4192878A4 (fr) Agents de liaison multispécifiques et leurs utilisations
EP3976656A4 (fr) Protéines de liaison à alk7 et leurs utilisations
SG11202010388SA (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
MA71640A (fr) Protéines de liaison au récepteur cannabinoïde de type 1 et leurs utilisations
EP4263611A4 (fr) Molécules de liaison à ace6 et leurs utilisations
EP4013785A4 (fr) Protéines de liaison au complément c2 et leurs utilisations
EP4013793A4 (fr) Anticorps de liaison au récepteur frizzled et utilisations associées